Edik M. Blais
0000-0001-5609-3849
Publication & Citation Trends
Most Cited Works
Publications
76 total
Actionability landscape and biomarker utility in a colorectal cancer alliance cohort: Initial results from the Know Your Biomarker program.
Cited by 0
Semantic Scholar
Evaluating the Effect of KRAS Variants on Survival Outcomes and Therapy Response in Pancreatic Cancer
Cited by 2
Semantic Scholar
Validation of PDACai v2.0 in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC).
Cited by 0
Semantic Scholar
Clinical outcomes and molecular characteristics of lung-only and liver-only metastatic pancreatic cancer: results from a real-world evidence database OA
Cited by 5
Semantic Scholar
Association between TP53 gain of function and loss of function mutational subgroups and survival in pancreatic adenocarcinoma.
Cited by 0
Semantic Scholar
Keratin 17 modulates the immune topography of pancreatic cancer OA
Cited by 3
Semantic Scholar
Abstract PO5-06-04: EMSY amplification co-occurs with FGF/FGFR axis amplification in Metastatic Breast Cancer
Cited by 0
Semantic Scholar
Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma OA
Cited by 5
Semantic Scholar
Research Topics
Pancreatic and Hepatic Oncology Research
(37)
Cancer Genomics and Diagnostics
(33)
Cancer Cells and Metastasis
(8)
Neuroendocrine Tumor Research Advances
(8)
Renal cell carcinoma treatment
(7)
Frequent Co-Authors
Affiliations
Panthera Corporation
University of Virginia Health System
Central Maine Medical Center
Centre Hospitalier Universitaire de Sherbrooke
Xperi (Ireland)